Login to Your Account



EpiCept Shares Rise 38.6% on Ceplene Survival Analysis

By Tom Wall


Monday, December 13, 2010
EpiCept Corp. stock (NASDAQ:EPCT) climbed 38.6 percent, gaining 27 cents, to close at 97 cents Friday, following word from the Tarrytown, N.Y.-based company that a new analysis supported the favorable impact of Ceplene (histamine dihydrochloride) on overall survival and its activity with interleukin-2 (IL-2) in patients with acute myeloid leukemia (AML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription